Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006032 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00006032 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute.
The verdict
NCT00006032, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by autologous peripheral stem cell transplantation in treating women who have metastatic breast cancer.
Interventions
- DRUG etoposide
- DRUG ifosfamide
- PROCEDURE peripheral blood stem cell transplantation
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006032
The ClinicalTrials.gov registry entry for NCT00006032 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which etoposide is the first listed.
NCT00006032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006032 about?
NCT00006032 is a clinical study titled "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00006032?
This trial is currently terminated. It is a Phase 2 study. The study started on 2000-03. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00006032?
The interventions under investigation include: etoposide (DRUG), ifosfamide (DRUG), peripheral blood stem cell transplantation (PROCEDURE), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006032?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.